Obesity Trial, Recruiting NCT05806801 Sponsor: University of Michigan Condition: Obesity
Back to Obesity

Obesity Trial, Recruiting

NCT05806801
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 40 years old
  • People with a Body Mass Index (BMI) between 30 and 40 (a measure of body weight relative to height)
  • People whose weight has been stable — changing by no more than 3kg — for at least approximately 2 months
  • People who do not have a regularly planned exercise or physical activity routine
  • Women must have regular menstrual periods and must not have gone through menopause

Who may not be able to join:

  • People with abnormal results on a heart electrical activity test (EKG/ECG)
  • People with a history or current evidence of heart disease, diabetes, or other conditions affecting metabolism
  • People taking medications known to affect fat (lipid) or blood sugar (glucose) levels
  • People who are pregnant or currently breastfeeding
  • People who use tobacco products or e-cigarettes
  • People who have previously had a bad reaction (hypersensitivity) to insulin, human albumin, or potassium chloride injection
  • People with allergies or sensitivities to a certain group of local anaesthetics called amide-type anaesthetics (for example, lidocaine)
  • People who have a history of high potassium levels in the blood (hyperkalemia), or who may be at risk of developing it — including those taking certain medications such as cardiac glycosides or potassium-sparing diuretics
  • People taking blood-thinning (anti-coagulant) medications (such as Coumadin or Rivaroxaban), or people with a known allergy or sensitivity to lidocaine, are not eligible for the biopsy part of this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jeffrey Horowitz, PhD, University of Michigan

Phone: 734-647-9850

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
19 July 2023
Est. completion
1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Insulin sensitivity; Fatty acid turnover; Adipose tissue capillarization; Adipose tissue fibrosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov